Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients

We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy. Postmenopausal osteoporosis patients with a high risk of fracture—154 in total—were recruited; their...